Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Pharmacogenetics and individualized therapy [[electronic resource] /] / edited by Anke-Hilse Maitland-van der Zee, Ann K. Daly
| Pharmacogenetics and individualized therapy [[electronic resource] /] / edited by Anke-Hilse Maitland-van der Zee, Ann K. Daly |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2011 |
| Descrizione fisica | 1 online resource (506 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
Maitland-van der ZeeAnke-Hilse
DalyAnn K |
| Soggetto topico | Pharmacogenetics |
| ISBN |
1-280-59050-5
9786613620330 1-118-11648-8 1-118-11649-6 1-118-11646-1 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Pharmacogenetics : a historical perspective / A.K. Daly -- Pharmacogenetics in drug metabolism : role of phase I enzymes / V. Dolzan -- Pharmacogenetics of phase II drug metabolizing enzymes / I. Cascorbi -- Pharmacogenetics of drug transporters / Henriette E. Meyer zu Schwabedissen, Markus Grube, Heyo K. Kroemer -- Pharmacogenetics of drug targets / M.Arranz and A. Daly -- Cardiovascular pharmacogenetics / Bas J.M. Peters ... [et al.] -- Pharmacogenetics in psychiatry / Evangelia M. Tsapakis ... [et al.] -- Pharmacogenetics in cancer / S. Marsh -- Pharmacogenetics of asthma and COPD / E. Koster ... [et al.] -- Pharmacogenetics of adverse drug reactions / Ann K Daly, Martin Armstrong, and Munir Pirmohamed -- Pharmacogenomics of inflammatory bowel diseaes / Alexander Teml ... [et al.] -- Pharmacogenetics of pain medication / J. Loetsch -- Ethical and social issues in pharmacogenomics testing / S. Vijverberg, T. Pieters, and M. Cornel -- High-throughput genotyping technologies for pharmacogenetics / Beatriz Sobrino and Dr. Angel Carracedo -- Developments in analyses in pharmacogenetic datasets / A. Motsinger -- Applications of pharmacogenetics in pharmaceutical research and development / Daniel K. Burns and Scott S. Sundseth -- Role of pharmacogenetics in registration process / Myong-Jin Kim ... [et al.] -- Pharmacogenetics : possibilities and pitfalls / A.H. Maitland-van der Zee and A.K. Daly. |
| Record Nr. | UNINA-9910141298403321 |
| Hoboken, N.J., : John Wiley & Sons, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pharmacogenetics and individualized therapy [[electronic resource] /] / edited by Anke-Hilse Maitland-van der Zee, Ann K. Daly
| Pharmacogenetics and individualized therapy [[electronic resource] /] / edited by Anke-Hilse Maitland-van der Zee, Ann K. Daly |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2011 |
| Descrizione fisica | 1 online resource (506 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
Maitland-van der ZeeAnke-Hilse
DalyAnn K |
| Soggetto topico | Pharmacogenetics |
| ISBN |
1-280-59050-5
9786613620330 1-118-11648-8 1-118-11649-6 1-118-11646-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Pharmacogenetics : a historical perspective / A.K. Daly -- Pharmacogenetics in drug metabolism : role of phase I enzymes / V. Dolzan -- Pharmacogenetics of phase II drug metabolizing enzymes / I. Cascorbi -- Pharmacogenetics of drug transporters / Henriette E. Meyer zu Schwabedissen, Markus Grube, Heyo K. Kroemer -- Pharmacogenetics of drug targets / M.Arranz and A. Daly -- Cardiovascular pharmacogenetics / Bas J.M. Peters ... [et al.] -- Pharmacogenetics in psychiatry / Evangelia M. Tsapakis ... [et al.] -- Pharmacogenetics in cancer / S. Marsh -- Pharmacogenetics of asthma and COPD / E. Koster ... [et al.] -- Pharmacogenetics of adverse drug reactions / Ann K Daly, Martin Armstrong, and Munir Pirmohamed -- Pharmacogenomics of inflammatory bowel diseaes / Alexander Teml ... [et al.] -- Pharmacogenetics of pain medication / J. Loetsch -- Ethical and social issues in pharmacogenomics testing / S. Vijverberg, T. Pieters, and M. Cornel -- High-throughput genotyping technologies for pharmacogenetics / Beatriz Sobrino and Dr. Angel Carracedo -- Developments in analyses in pharmacogenetic datasets / A. Motsinger -- Applications of pharmacogenetics in pharmaceutical research and development / Daniel K. Burns and Scott S. Sundseth -- Role of pharmacogenetics in registration process / Myong-Jin Kim ... [et al.] -- Pharmacogenetics : possibilities and pitfalls / A.H. Maitland-van der Zee and A.K. Daly. |
| Record Nr. | UNINA-9910824578403321 |
| Hoboken, N.J., : John Wiley & Sons, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Principles and practice of pharmaceutical medicine [[electronic resource] /] / edited by Lionel D. Edwards, Anthony W. Fox, Peter D. Stonier
| Principles and practice of pharmaceutical medicine [[electronic resource] /] / edited by Lionel D. Edwards, Anthony W. Fox, Peter D. Stonier |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Oxford, U.K., : Wiley-Blackwell, 2011 |
| Descrizione fisica | 1 online resource (801 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) |
EdwardsLionel D
FoxAnthony W. <1956-> StonierP. D |
| Soggetto topico |
Drug development
Drugs - Research Pharmacology |
| ISBN |
1-4443-4812-4
1-282-88432-8 9786612884320 1-4443-2526-4 1-4443-2527-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section 1. Overview of pharmaceutical medicine -- section 2. Drug discovery and development -- section 3. Special populations and required special studies -- section 4. Applied aspects -- section 5. Drug regulation -- section 6. Medical services -- section 7. Legal and ethical aspects of pharmaceutical medicine -- section 8. Business aspects. |
| Record Nr. | UNINA-9910140911403321 |
| Oxford, U.K., : Wiley-Blackwell, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Principles of organic medicinal chemistry [[electronic resource] /] / Rama Rao Nadendla
| Principles of organic medicinal chemistry [[electronic resource] /] / Rama Rao Nadendla |
| Autore | Nadendla Rama Rao |
| Pubbl/distr/stampa | New Delhi, : New Age International, 2005 |
| Descrizione fisica | 1 online resource (331 p.) |
| Disciplina | 615/.19 |
| Soggetto topico |
Pharmaceutical chemistry
Chemistry, Organic |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-78890-2
9786611788902 81-224-2485-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Preface; Contents; Chapter 1 Introduction to Medicinal Chemistry; Chapter 2 General Principles of Drug Action; Chapter 3 Physico-chemical Properties of Organic Medicinal Agents; Chapter 4 Chemistry of Prodrugs; Chapter 5 Drug Metabolism; Chapter 6 General Anesthetics; Chapter 7 Sedative-Hypnotic Drugs; Chapter 8 Phychoactive Drugs; Chapater 9 Antiepileptic Agents; Chapter 10 Cholinergic and Anticholinergic Drugs; Chapter 11 Adrenergic Drugs; Chapter 12 Adrenoreceptor Blocking Agents; Chapter 13 Skeletal Muscle Relaxants; Chapter 14 Antihistamines; Chapter 15 Narcotic Analgesics
Chapter 16 Narcotic AntagonistsChapter 17 Antitussives; Chapter 18 Non-Steroidal Antiinflammatory Drugs (NSAIDs); Chapter 19 Local Anesthetics; Chapter 20 Diuretics; Chapter 21 Hypoglycemic Agents; Chapter 22 Thyroid and Antithyroid Drugs; Practice Questions; References; Index |
| Record Nr. | UNINA-9910454544503321 |
Nadendla Rama Rao
|
||
| New Delhi, : New Age International, 2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Principles of organic medicinal chemistry / / Rama Rao Nadendla
| Principles of organic medicinal chemistry / / Rama Rao Nadendla |
| Autore | Nadendla Rama Rao |
| Pubbl/distr/stampa | New Delhi, : New Age International, 2005 |
| Descrizione fisica | 1 online resource (322 pages) : illustrations |
| Disciplina | 615/.19 |
| Soggetto topico |
Pharmaceutical chemistry
Chemistry, Organic |
| ISBN |
1-281-78890-2
9786611788902 81-224-2485-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Preface; Contents; Chapter 1 Introduction to Medicinal Chemistry; Chapter 2 General Principles of Drug Action; Chapter 3 Physico-chemical Properties of Organic Medicinal Agents; Chapter 4 Chemistry of Prodrugs; Chapter 5 Drug Metabolism; Chapter 6 General Anesthetics; Chapter 7 Sedative-Hypnotic Drugs; Chapter 8 Phychoactive Drugs; Chapater 9 Antiepileptic Agents; Chapter 10 Cholinergic and Anticholinergic Drugs; Chapter 11 Adrenergic Drugs; Chapter 12 Adrenoreceptor Blocking Agents; Chapter 13 Skeletal Muscle Relaxants; Chapter 14 Antihistamines; Chapter 15 Narcotic Analgesics
Chapter 16 Narcotic Antagonists; Chapter 17 Antitussives; Chapter 18 Non-Steroidal Antiinflammatory Drugs (NSAIDs); Chapter 19 Local Anesthetics; Chapter 20 Diuretics; Chapter 21 Hypoglycemic Agents; Chapter 22 Thyroid and Antithyroid Drugs; Practice Questions; References; Index |
| Record Nr. | UNINA-9910782798403321 |
|
Nadendla Rama Rao
|
||
| New Delhi, : New Age International, 2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Principles of organic medicinal chemistry / / Rama Rao Nadendla
| Principles of organic medicinal chemistry / / Rama Rao Nadendla |
| Autore | Nadendla Rama Rao |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | New Delhi, : New Age International, 2005 |
| Descrizione fisica | 1 online resource (322 pages) : illustrations |
| Disciplina | 615/.19 |
| Soggetto topico |
Pharmaceutical chemistry
Chemistry, Organic |
| ISBN |
1-281-78890-2
9786611788902 81-224-2485-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Preface; Contents; Chapter 1 Introduction to Medicinal Chemistry; Chapter 2 General Principles of Drug Action; Chapter 3 Physico-chemical Properties of Organic Medicinal Agents; Chapter 4 Chemistry of Prodrugs; Chapter 5 Drug Metabolism; Chapter 6 General Anesthetics; Chapter 7 Sedative-Hypnotic Drugs; Chapter 8 Phychoactive Drugs; Chapater 9 Antiepileptic Agents; Chapter 10 Cholinergic and Anticholinergic Drugs; Chapter 11 Adrenergic Drugs; Chapter 12 Adrenoreceptor Blocking Agents; Chapter 13 Skeletal Muscle Relaxants; Chapter 14 Antihistamines; Chapter 15 Narcotic Analgesics
Chapter 16 Narcotic Antagonists; Chapter 17 Antitussives; Chapter 18 Non-Steroidal Antiinflammatory Drugs (NSAIDs); Chapter 19 Local Anesthetics; Chapter 20 Diuretics; Chapter 21 Hypoglycemic Agents; Chapter 22 Thyroid and Antithyroid Drugs; Practice Questions; References; Index |
| Record Nr. | UNINA-9910809824103321 |
|
Nadendla Rama Rao
|
||
| New Delhi, : New Age International, 2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Process scale purification of antibodies [[electronic resource] /] / edited by Uwe Gottschalk
| Process scale purification of antibodies [[electronic resource] /] / edited by Uwe Gottschalk |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (458 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) | GottschalkUwe |
| Soggetto topico |
Monoclonal antibodies - Purification
Biochemical engineering |
| ISBN |
1-118-21074-3
1-282-00919-2 9786612009198 0-470-44489-4 0-470-44488-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
PROCESS SCALE PURIFICATION OF ANTIBODIES; CONTENTS; Preface; About the Author; Contributors; 1 Downstream Processing of Monoclonal Antibodies: Current Practices and Future Opportunities; 1.1 Introduction; 1.2 A Brief History of cGMP mAb and Intravenous Immunoglobulin (IgIV) Purification; 1.3 Current Approaches in Purification Process Development: Impact of Platform Processes; 1.4 Typical Unit Operations and Processing Alternatives; 1.5 VLS Processes: Ton-Scale Production and Beyond; 1.6 Process Validation; 1.7 Product Life Cycle Management; 1.8 Future Opportunities; 1.9 Conclusions
1.10 Acknowledgments1.11 References; 2 The Development of Antibody Purification Technologies; 2.1 Introduction; 2.2 Chromatographic Purification of Antibodies before Protein A; 2.3 Antibody Purification after 1975; 2.4 Additional Technologies for Antibody Purification; 2.5 Purification of mAbS Approved in North America and in Europe; 2.6 Acknowledgments; 2.7 References; 3 Harvest and Recovery of Monoclonal Antibodies: Cell Removal and Clarification; 3.1 Introduction; 3.2 Centrifugation; 3.3 Microfiltration; 3.4 Depth Filtration; 3.5 Flocculation; 3.6 Absolute Filtration 3.7 Expanded-Bed Chromatography3.8 Comparison of Harvest and Clarification Unit Operations; 3.9 Acknowledgments; 3.10 References; 4 Protein A-Based Affinity Chromatography; 4.1 Introduction; 4.2 Properties of Protein A and Commercially Available Protein A Resins; 4.2.1 Protein A Structure; 4.2.2 Protein A-Immunoglobulin G (IgG) Interaction; 4.2.3 Stoichiometry of Protein A-IgG Binding; 4.2.4 Protein A Stability; 4.2.5 Commercial Protein A Resins; 4.2.6 Static Capacity; 4.2.7 DBC; 4.2.8 Leaching; 4.2.9 Production Rates; 4.3 Protein A Chromatography Step Development; 4.3.1 Loading/Binding 4.3.2 Wash Development4.3.3 Elution; 4.3.4 Stripping; 4.3.5 Regeneration and CIP; 4.4 Additional Considerations During Development and Scale-Up; 4.4.1 Controlling HMW Formation; 4.4.2 Removal of Soluble HMW Contaminants; 4.4.3 Turbidity; 4.5 Virus Removal/Inactivation; 4.5.1 Virus Removal; 4.5.2 Low-pH Inactivation; 4.5.3 Bovine/Transmissible Spongiform Encephalopathy (BSE/TSE) Clearance; 4.6 Validation and Robustness; 4.6.1 Validation; 4.6.2 Robustness; 4.7 Conclusions; 4.8 Acknowledgments; 4.9 References; 5 Purification of Human Monoclonal Antibodies: Non-Protein A Strategies 5.1 Introduction5.2 Integrated Process Designs for Human Monoclonal Antibody (HuMab) Production; 5.3 Purification Process Designs for HuMabs; 5.3.1 Protein A Purification Schemes; 5.3.2 Non-Protein A Purification Schemes; 5.3.3 Host Cell Protein (HCP) Exclusion Approach for Ion-Exchange Purification Schemes; 5.4 Conclusions; 5.5 Acknowledgments; 5.6 References; 6 Purification of Monoclonal Antibodies by Mixed-Mode Chromatography; 6.1 Introduction; 6.2 A Brief History; 6.3 Prerequisites for Industrial Implementation; 6.4 Mechanisms, Screening, and Method Development; 6.5 Capture Applications 6.6 Polishing Applications |
| Record Nr. | UNINA-9910782895903321 |
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Process scale purification of antibodies [[electronic resource] /] / edited by Uwe Gottschalk
| Process scale purification of antibodies [[electronic resource] /] / edited by Uwe Gottschalk |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (458 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) | GottschalkUwe |
| Soggetto topico |
Monoclonal antibodies - Purification
Biochemical engineering |
| ISBN |
1-118-21074-3
1-282-00919-2 9786612009198 0-470-44489-4 0-470-44488-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
PROCESS SCALE PURIFICATION OF ANTIBODIES; CONTENTS; Preface; About the Author; Contributors; 1 Downstream Processing of Monoclonal Antibodies: Current Practices and Future Opportunities; 1.1 Introduction; 1.2 A Brief History of cGMP mAb and Intravenous Immunoglobulin (IgIV) Purification; 1.3 Current Approaches in Purification Process Development: Impact of Platform Processes; 1.4 Typical Unit Operations and Processing Alternatives; 1.5 VLS Processes: Ton-Scale Production and Beyond; 1.6 Process Validation; 1.7 Product Life Cycle Management; 1.8 Future Opportunities; 1.9 Conclusions
1.10 Acknowledgments1.11 References; 2 The Development of Antibody Purification Technologies; 2.1 Introduction; 2.2 Chromatographic Purification of Antibodies before Protein A; 2.3 Antibody Purification after 1975; 2.4 Additional Technologies for Antibody Purification; 2.5 Purification of mAbS Approved in North America and in Europe; 2.6 Acknowledgments; 2.7 References; 3 Harvest and Recovery of Monoclonal Antibodies: Cell Removal and Clarification; 3.1 Introduction; 3.2 Centrifugation; 3.3 Microfiltration; 3.4 Depth Filtration; 3.5 Flocculation; 3.6 Absolute Filtration 3.7 Expanded-Bed Chromatography3.8 Comparison of Harvest and Clarification Unit Operations; 3.9 Acknowledgments; 3.10 References; 4 Protein A-Based Affinity Chromatography; 4.1 Introduction; 4.2 Properties of Protein A and Commercially Available Protein A Resins; 4.2.1 Protein A Structure; 4.2.2 Protein A-Immunoglobulin G (IgG) Interaction; 4.2.3 Stoichiometry of Protein A-IgG Binding; 4.2.4 Protein A Stability; 4.2.5 Commercial Protein A Resins; 4.2.6 Static Capacity; 4.2.7 DBC; 4.2.8 Leaching; 4.2.9 Production Rates; 4.3 Protein A Chromatography Step Development; 4.3.1 Loading/Binding 4.3.2 Wash Development4.3.3 Elution; 4.3.4 Stripping; 4.3.5 Regeneration and CIP; 4.4 Additional Considerations During Development and Scale-Up; 4.4.1 Controlling HMW Formation; 4.4.2 Removal of Soluble HMW Contaminants; 4.4.3 Turbidity; 4.5 Virus Removal/Inactivation; 4.5.1 Virus Removal; 4.5.2 Low-pH Inactivation; 4.5.3 Bovine/Transmissible Spongiform Encephalopathy (BSE/TSE) Clearance; 4.6 Validation and Robustness; 4.6.1 Validation; 4.6.2 Robustness; 4.7 Conclusions; 4.8 Acknowledgments; 4.9 References; 5 Purification of Human Monoclonal Antibodies: Non-Protein A Strategies 5.1 Introduction5.2 Integrated Process Designs for Human Monoclonal Antibody (HuMab) Production; 5.3 Purification Process Designs for HuMabs; 5.3.1 Protein A Purification Schemes; 5.3.2 Non-Protein A Purification Schemes; 5.3.3 Host Cell Protein (HCP) Exclusion Approach for Ion-Exchange Purification Schemes; 5.4 Conclusions; 5.5 Acknowledgments; 5.6 References; 6 Purification of Monoclonal Antibodies by Mixed-Mode Chromatography; 6.1 Introduction; 6.2 A Brief History; 6.3 Prerequisites for Industrial Implementation; 6.4 Mechanisms, Screening, and Method Development; 6.5 Capture Applications 6.6 Polishing Applications |
| Record Nr. | UNINA-9910819255503321 |
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Prokaryotic toxin-antitoxins [[electronic resource] /] / Kenn Gerdes, editor
| Prokaryotic toxin-antitoxins [[electronic resource] /] / Kenn Gerdes, editor |
| Pubbl/distr/stampa | Heidelberg, : Springer, 2013 |
| Descrizione fisica | 1 online resource (362 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) | GerdesKenn |
| Soggetto topico |
Toxins
Medical microbiology |
| ISBN | 3-642-33253-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Type I Toxin – Antitoxin Systems: Hok/Sok and Fst -- Novel Type I Toxin – Antitoxin Systems -- Type II TA Loci: The Ccdab and Parde Families -- Type II TA Loci: The Relbe Family -- Type II TA Loci: The Unusual Mqsra Locus -- Type II TA Loci: The Mazef Family -- Type II TA Loci: Vapbc and Other TA Loci In Mycobacteria -- Type II TA Loci: Phd Doc Family -- Type II TA Loci: The Fic Family -- Type II TA Loci, Hipab And Persisters -- Type II TA Loci: Zeta/Pezt Family -- Type II Loci: Phylogeny -- Type III TA Loci -- TA Loci Encoded By Plasmids -- TA Loci in Archaea -- TA Loci in Mycobacterium Tuberculosis -- TA Loci in Streptococcus Pneumoniae -- Biotechnological and Medical Exploitations Of TA Genes and Their Components. |
| Record Nr. | UNINA-9910437845303321 |
| Heidelberg, : Springer, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Protein and peptide mass spectrometry in drug discovery [[electronic resource] /] / edited by Michael L. Gross, Guodong Chen, Birendra N. Pramanik
| Protein and peptide mass spectrometry in drug discovery [[electronic resource] /] / edited by Michael L. Gross, Guodong Chen, Birendra N. Pramanik |
| Pubbl/distr/stampa | Hoboken, NJ, : Wiley, c2012 |
| Descrizione fisica | 1 online resource (496 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
GrossMichael L
ChenGuodong <1966-> PramanikBirendra N. <1944-> |
| Soggetto topico |
Drug development
Peptides - Spectra Proteins - Spectra |
| ISBN |
1-283-28278-X
9786613282781 1-118-11654-2 1-118-11655-0 1-118-11653-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Protein and Peptide Mass Spectrometry in Drug Discovery; CONTENTS; PREFACE; CONTRIBUTORS; PART I: METHODOLOGY; 1 Ionization Methods in Protein Mass Spectrometry; 1.1 History of the Development of Protein Mass Spectrometry; 1.2 Laser-Based Ionization Methods for Proteins; 1.2.1 Matrix-Assisted Laser Desorption/Ionization (MALDI); 1.2.2 Atmospheric Pressure Matrix-Assisted Laser Desorption/Ionization (AP-MALDI); 1.2.3 Surface-Enhanced Laser Desorption/Ionization (SELDI); 1.2.4 Nanostructure-Initiator Mass Spectrometry (NIMS); 1.3 Spray-Based Ionization Methods for Proteins
1.3.1 Electrospray Ionization (ESI)1.3.2 Sonic Spray Ionization (SSI); 1.3.3 Electrosonic Spray Ionization (ESSI); 1.4 Ambient Ionization Methods; 1.4.1 Desorption Electrospray Ionization (DESI); 1.4.2 Fused-Droplet Electrospray Ionization (FD-ESI); 1.4.3 Electrospray-Assisted Laser Desorption Ionization (ELDI); 1.4.4 Matrix-Assisted Laser Desorption Electrospray Ionization (MALDESI); 1.5 Conclusions; Acknowledgments; References; 2 Ion Activation and Mass Analysis in Protein Mass Spectrometry; 2.1 Introduction; 2.1.1 Mass Accuracy; 2.1.2 Mass Resolving Power; 2.1.3 Mass Range 2.1.4 Scan Speed2.1.5 Tandem MS Analysis; 2.2 Ion Activation and Tandem MS Analysis; 2.2.1 Introduction: Fragmentation in Protein MS; 2.2.2 Collisional Activation Methods; 2.2.3 Photodissociation; 2.2.4 Electron-Induced Dissociation; 2.2.5 Other Radical-Induced Fragmentation Methods; 2.3 Mass Analyzers; 2.3.1 Time-of-Flight Mass Analyzer; 2.3.2 Quadrupole Mass Analyzer and Quadrupole Ion Trap; 2.3.3 Fourier-Transform Ion Cyclotron Resonance Mass Spectrometer; 2.3.4 Orbitrap; 2.3.5 Ion-Mobility Instruments; References; 3 Target Proteins: Bottom-up and Top-down Proteomics 3.1 Mass Spectral Approaches to Targeted Protein Identification3.2 Bottom-up Proteomics; 3.2.1 Peptide Mass Fingerprinting; 3.2.2 Bottom-up Proteomics Using Tandem MS: GeLC-MS/MS and Shotgun Digests; 3.2.3 GeLC-MS/MS; 3.2.4 Shotgun Digest; 3.3 Top-down Approaches; 3.4 Next-Generation Approaches; References; 4 Quantitative Proteomics by Mass Spectrometry; 4.1 Introduction; 4.2 In-Cell Labeling; 4.2.1 15N Metabolic Labeling; 4.2.2 Stable Isotope Labeling by Amino Acid (SILAC); 4.3 Quantitation via Isotopic Labeling of Proteins; 4.3.1 2D PAGE-Based Quantitation 4.3.2 Proteolytic Labeling Using 18O Water4.3.3 Quantitative Labeling by Chemical Tagging; 4.4 Quantitation via Isotopic Labeling on Peptides; 4.4.1 ICAT; 4.4.2 iTRAQ; 4.4.3 SoPIL; 4.4.4 Absolute Quantitation; 4.5 Label-Free Quantitation; 4.6 Conclusions; Acknowledgment; References; 5 Comparative Proteomics by Direct Tissue Analysis Using Imaging Mass Spectrometry; 5.1 Introduction; 5.2 Conventional Comparative Proteomics; 5.3 Comparative Proteomics Using Imaging MS; 5.3.1 Biomarker Discovery: Breast Cancer; 5.3.2 Biomarker Discovery: Toxicity; 5.3.3 Correlating Drug and Protein Distributions 5.4 Conclusions |
| Record Nr. | UNINA-9910141237703321 |
| Hoboken, NJ, : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
